Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
Disease control
Recruiting now
This phase 2 trial is testing whether adding a targeted therapy called fumetinib to chemotherapy before standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that has EGFR mutations and cannot be removed by surgery. Participants are ran…
Phase: PHASE2 • Sponsor: Peng Zhang • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC